Goullé J-P, Verstraete A, Boulu R, Costentin J, Foucher J-P, Raes E, Tillement J-P
Groupe de travail stupéfiants, médicaments et sécurité routière de l'Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris, France.
Ann Pharm Fr. 2008 Aug;66(4):196-205. doi: 10.1016/j.pharma.2008.06.002. Epub 2008 Aug 23.
The European Union (EU) has 25 member-states and 455 million inhabitants. Statistics on traffic accidents in the EU show that more than 45,000 people are killed annually, including 5200 in France. At the same time, nearly two million persons in the EU require medical treatment for traffic-accident-related injuries, including 109,000 in France. In addition, traffic accidents are the major cause of death of those individuals aged 15 to 24 years. One third of the EU inhabitants will be hospitalized during their life due to a traffic accident with a cost over 160 billion euro (2-3% of the Gross Domestic Product). An important contributing factor to crashes is the use of alcohol and/or illicit drugs or medication when driving, as they exert negative effects on cognition and psychomotor functions. For illicit drugs, abuse of cannabis with or without alcohol is a major concern for the EU. In fact, three million Europeans use cannabis daily and 80% of them drive after use. A number of French studies since 1999 have underlined the high prevalence of cannabis found in the blood of injured or killed drivers. From medical or judicial observations, it is clear that cannabis use increases the risk of traffic accidents. Many groups outside Europe have also shown the association between drug abuse and crashes. The number of casualties related to certain medicines, especially benzodiazepines remains at a high level, particularly in the elderly. In many countries the prevalence of medicinal drugs associated with car accidents is higher than with cannabis. Annex III of the European Union Council Directive of July the 29th 1991 in fact states that a driving license should not be issued to or renewed for applicants or drivers who are dependent on psychotropic substances or use them regularly. Recently, France has categorized the medicinal drugs available in the country by using three pictograms: level one yellow, "be careful"; level two orange, "be very careful"; level three red, "don't drive". It is an important campaign that increases awareness among the public and the medical professionals about the potential dangerous effects of medicinal drugs when driving. The EU objective of reducing the number of fatalities to 25,000 by 2010 will require strengthening measures against the use of alcohol, illicit and medicinal drugs by not well-informed drivers. It is not only a really great challenge, but also a significant investment towards improving public health in France as well as in Europe.
欧盟有25个成员国,4.55亿人口。欧盟的交通事故统计数据显示,每年有超过4.5万人丧生,其中法国有5200人。与此同时,欧盟近200万人因交通事故受伤需要接受治疗,其中法国有10.9万人。此外,交通事故是15至24岁人群的主要死因。欧盟三分之一的居民一生中会因交通事故住院,费用超过1600亿欧元(占国内生产总值的2 - 3%)。导致撞车的一个重要因素是开车时使用酒精和/或非法药物或药品,因为它们会对认知和精神运动功能产生负面影响。对于非法药物,无论是否饮酒,大麻滥用都是欧盟的一个主要担忧。事实上,300万欧洲人每天使用大麻,其中80%在使用后开车。自1999年以来,法国的多项研究强调了在受伤或死亡司机血液中发现大麻的高比例。从医学或司法观察来看,显然使用大麻会增加交通事故风险。欧洲以外的许多团体也表明了药物滥用与撞车之间的关联。与某些药物,尤其是苯二氮䓬类药物相关的伤亡人数仍然居高不下,在老年人中尤为如此。在许多国家,与车祸相关的药用药物的流行率高于大麻。1991年7月29日欧盟理事会指令的附件三实际上规定,对于依赖精神药物或经常使用精神药物的申请人或司机,不应发放驾驶执照或更新其驾驶执照。最近,法国通过使用三个象形图对该国现有的药用药物进行了分类:一级黄色,“小心”;二级橙色,“非常小心”;三级红色,“不要开车”。这是一项重要的活动,提高了公众和医疗专业人员对药用药物在驾驶时潜在危险影响的认识。欧盟到2010年将死亡人数减少到25000人的目标将需要加强措施,以防止不知情的司机使用酒精、非法和药用药物。这不仅是一个巨大的挑战,也是对改善法国乃至欧洲公众健康的一项重大投资。